Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale

被引：68

作者：

Bagri, Anil ^{[1
]}

Kouros-Mehr, Hosein ^{[1
]}

Leong, Kevin G. ^{[1
]}

Plowman, Greg D. ^{[1
]}

机构：

[1] Genentech Inc, Tumor Biol & Angiogenesis Dept, San Francisco, CA 94080 USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2010年 / 16卷 / 03期

关键词：

ENDOTHELIAL GROWTH-FACTOR; METASTATIC COLORECTAL-CANCER; BEVACIZUMAB PLUS IRINOTECAN; PRIMARY BREAST-CANCER; PHASE-II TRIAL; TUMOR ANGIOGENESIS; ANTIANGIOGENIC THERAPY; COLON-CANCER; INTERSTITIAL HYPERTENSION; VASCULAR NORMALIZATION;

D O I：

10.1016/j.molmed.2010.01.004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Several ongoing clinical studies are designed to test the efficacy of antiangiogenic therapies in the adjuvant setting, where the goal is to increase the cure rate in patients who have just undergone surgical resection of all visible disease. Tumors depend on angiogenesis to support their growth and progression and blockade of this process has proven to be a valid strategy for treating multiple types of advanced metastatic cancer. However, results from the first of these clinical adjuvant studies were disappointing, stimulating extensive debate as to the potential of this approach. It will require additional clinical studies before we realize whether the effects of angiogenic blockade are durable, and if they are able to cure a subset of patients with early stage cancer.

引用

页码：122 / 132

页数：11

共 83 条

[1] Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Colangelo, Linda H. ;

Lopa, Samia H. ;

Petrelli, Nicholas J. ;

Goldberg, Richard M. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3385-3390

[2] Transcriptional Switch of Dormant Tumors to Fast-Growing Angiogenic Phenotype [J].

Almog, Nava ;

Ma, Lili ;

Raychowdhury, Raktima ;

Schwager, Christian ;

Erber, Ralf ;

Short, Sarah ;

Hlatky, Lynn ;

Vajkoczy, Peter ;

Huber, Peter E. ;

Folkman, Judah ;

Abdollahi, Amir .

CANCER RESEARCH, 2009, 69 (03) :836-844

[3] Neuropilins in Tumor Biology [J].

Bagri, Anil ;

Tessier-Lavigne, Marc ;

Watts, Ryan J. .

CLINICAL CANCER RESEARCH, 2009, 15 (06) :1860-1864

[4] Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor [J].

Bao, Shideng ;

Wu, Qiulian ;

Sathornsumetee, Sith ;

Hao, Yueling ;

Li, Zhizhong ;

Hjelmeland, Anita B. ;

Shi, Oing ;

McLendon, Roger E. ;

Bigner, Darell D. ;

Rich, Jeremy N. .

CANCER RESEARCH, 2006, 66 (16) :7843-7848

[5] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[6] CHEMOTHERAPY Adding oxaliplatin to the equation [J].

Benson, B. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (11) :620-622

[7] Tumorigenesis and the angiogenic switch [J].

Bergers, G ;

Benjamin, LE .

NATURE REVIEWS CANCER, 2003, 3 (06) :401-410

[8]

Boucher Y, 1996, CANCER RES, V56, P4264

[9] Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J].

Casanovas, O ;

Hicklin, DJ ;

Bergers, G ;

Hanahan, D .

CANCER CELL, 2005, 8 (04) :299-309

[10] Improving long-term outcomes for patients with liver metastases from colorectal cancer [J].

Chong, G ;

Cunningham, D .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9063-9066

← 1 2 3 4 5 6 7 8 9 →